An experimental vaccine using mRNA technology has shown significant promise in preventing the recurrence of melanoma, the deadliest form of skin cancer, according to pharmaceutical companies Moderna and Merck. The vaccine, known as intisomeran, was tested in a large Phase 3 clinical trial involving 1,137 patients whose cancer had been surgically removed.
High-risk melanoma patients who received the experimental vaccine alongside Merck's immunotherapy drug Keytruda experienced improved outcomes in terms of remaining cancer-free for longer periods compared to those who received only Keytruda. While full study results have not yet been published, they are slated for presentation at an upcoming international medical meeting and submission to regulatory authorities.
Cancer researchers, who were not involved in the study, have expressed optimism about the development. Dr. Ashi Weeraratna, an expert in melanoma metastasis at John Hopkins Bloomberg School of Public Health, described the approach as potentially "transformational" due to its personalized nature. "It's very exciting because this approach is sort of really tailored to individual patient mutations," she stated.
The mRNA-based therapy allows for the rapid development of vaccines designed to train the immune system to identify and target specific cancer cells. This same technology was instrumental in the swift creation of COVID-19 vaccines. Intisomeran is individually designed to recognize and attack the unique mutations present in a patient's tumor, a characteristic that would make it the first vaccine of its kind if approved.
Another advantage of mRNA vaccines, according to Weeraratna, is their low incidence of side effects and toxicity compared to other immunotherapies. She highlighted the potential of the vaccine to address tumor dormancy, a phenomenon where cancer cells remain after treatment and can later return. "I think that's what's so exciting about this current therapy, is that it actually seems to be reducing the number of tumors that then come back after the initial therapies," she said.
Melanoma affects approximately 8,000 people annually in the U.S. While early detection generally leads to successful treatment, even patients diagnosed with early-stage melanoma can experience relapse. The Melanoma Research Alliance, which has supported some researchers involved in the trial, called the results "encouraging news for people affected by melanoma."